WikiDoc MAKES NO GUARANTEE OF VALIDITY. WikiDoc is not a professional health care provider, nor is it a suitable replacement for a licensed healthcare provider. WikiDoc is intended to be an educational tool, not a tool for any form of healthcare delivery. The educational content on WikiDoc drug pages is based upon the FDA package insert, National Library of Medicine content and practice guidelines / consensus statements. WikiDoc does not promote the administration of any medication or device that is not consistent with its labeling. Please read our full disclaimer here.
Overview
Topiramate is an antiepileptic drug that is FDA approved for the {{{indicationType}}} of partial seizures, primary generalized tonic-clonic seizures and lennox-gastaut syndrome. Common adverse reactions include paresthesia, anorexia, weight decrease, fatigue, dizziness, somnolence, nervousness, psychomotor slowing, difficulty with memory, difficulty with concentration/attention, cognitive problem, confusion, mood problems, fever, infection, and flushing.
Adult Indications and Dosage
FDA-Labeled Indications and Dosage (Adult)
Partial Onset Seizures
Monotherapy Use
The recommended dose for topiramate monotherapy in adults is 400 mg orally once daily. Titrate QUDEXY XR according to the following schedule:
T
Adjunctive Therapy Use
The recommended total daily dose of QUDEXY XR as adjunctive therapy in adults with partial onset seizures is 200 mg to 400 mg orally once daily.
Primary Generalized Tonic-Clonic Seizures
Monotherapy Use
The recommended dose for topiramate monotherapy in adults is 400 mg orally once daily. Titrate QUDEXY XR according to the following schedule:
T
Adjunctive Therapy Use
The recommended total dose for adults with primary generalized tonic-clonic seizures is 400 mg orally once daily.
Lennox-Gastaut Syndrome
Adjunctive Therapy Use
The recommended total daily dose of QUDEXY XR as adjunctive therapy in adults with Lennox-Gastaut Syndrome is 200 mg to 400 mg orally once daily.
Off-Label Use and Dosage (Adult)
Guideline-Supported Use
Condition1
Developed by:
Class of Recommendation:
Strength of Evidence:
Dosing Information
Dosage
Condition2
There is limited information regarding Off-Label Guideline-Supported Use of Topiramate in adult patients.
Non–Guideline-Supported Use
Condition1
Dosing Information
Dosage
Condition2
There is limited information regarding Off-Label Non–Guideline-Supported Use of Topiramate in adult patients.
Pediatric Indications and Dosage
FDA-Labeled Indications and Dosage (Pediatric)
Condition1
Dosing Information
Dosage
Condition2
There is limited information regarding FDA-Labeled Use of Topiramate in pediatric patients.
Off-Label Use and Dosage (Pediatric)
Guideline-Supported Use
Condition1
Developed by:
Class of Recommendation:
Strength of Evidence:
Dosing Information
Dosage
Condition2
There is limited information regarding Off-Label Guideline-Supported Use of Topiramate in pediatric patients.
Non–Guideline-Supported Use
Condition1
Dosing Information
Dosage
Condition2
There is limited information regarding Off-Label Non–Guideline-Supported Use of Topiramate in pediatric patients.
Contraindications
QUDEXY XR is contraindicated in patients with metabolic acidosis who are taking concomitant metformin.
Warnings
Description
Precautions
Description
Adverse Reactions
Clinical Trials Experience
There is limited information regarding Clinical Trial Experience of Topiramate in the drug label.
Body as a Whole
Cardiovascular
Digestive
Endocrine
Hematologic and Lymphatic
Metabolic and Nutritional
Musculoskeletal
Neurologic
Respiratory
Skin and Hypersensitivy Reactions
Special Senses
Urogenital
Miscellaneous
Postmarketing Experience
There is limited information regarding Postmarketing Experience of Topiramate in the drug label.